Stay updated with breaking news from Biomed res. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
2 1Department of Pediatrics and Child Health Nursing, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia 2Department of Maternity and Neonatal Health Nursing, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia 3Department of Midwifery, Reproductive Health, Debre Tabor University, Debre Tabor, Ethiopia Purpose: Maternal diabetes mellitus and the resulting adverse fetal outcomes including stillbirth in low- and middle-income countries (LMICs) are high. Thus, setting specific evidence is pivotal to plan, evaluate, and improve national preventive measures and to achieve international sustainable development goals. Therefore, this systematic review and meta-analysis was the first of its kind to estimate the pooled prevalence of stillbirth and its determinants among diabetic mothers in Ethiopia. ....
Frontiers | The Relevance of Genomic Epidemiology for Control of Tuberculosis in West Africa frontiersin.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from frontiersin.org Daily Mail and Mail on Sunday newspapers.
Fighting AGEs Formation: Upcycled Artichoke Inhibits Glycation, Increases Skin Firmness cosmeticsandtoiletries.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cosmeticsandtoiletries.com Daily Mail and Mail on Sunday newspapers.
Forxiga recommended for approval in the EU by CHMP for the treatment of patients with chronic kidney disease pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
for the treatment of patients with chronic kidney disease
for millions of people in the EU suffering from chronic kidney disease
AstraZeneca s Forxiga (dapagliflozin) has been recommended for approval in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D).
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion on results from the DAPA-CKD Phase III trial that showed Forxiga, on top of standard-of-care treatment with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, reduced the risk of the composite of worsening of renal function, end-stage kidney disease (ESKD) and cardiovascular (CV) or renal death, compared to placebo. ....